A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Darifenacin

Criteria

Inclusion Criteria:

• Adult patients with overactive bladder who completed a previous darifenacin short-term trial.

• Patients capable of independent toileting and able of independently completing the patient diary.

Exclusion Criteria:

• Patients in whom the use of anticholinergic drugs was contraindicated

• Evidence of severe liver disease

• Patients with other clinically significant urinary or gynecological conditions

Other protocol-defined inclusion/exclusion criteria may apply.